Radioiodine refractory (RAIR) is the major cause of thyroid cancer-related death. In order to avoid needless Radioiodine (RAI) therapy, recognizing the RAIR cases in time is important for the patients to obtain more time for the effective therapy.
Introduction
Thyroid nodules are a very common medical problem with a prevalence of 19% to 68% in the general population. [1, 2] Approximately 7% to 15% of thyroid nodules are thyroid cancer, and it has been estimated that 96% of all new endocrine organ cancers originate from the thyroid gland. [3, 4] Despite the generally favorable course of thyroid cancer, up to 10% to 30% of patients with differentiated thyroid cancer (DTC) may have recurrence, including local recurrence and distant metastases. For these patients, there are multiple therapeutic options, such as surgery, radioactive iodine (RAI) therapy, and radiotherapy. [5] However, only about 30% of these patients had a complete response (according to response evaluation criteria in solid tumors 1.1, RECIST 1.1). The remaining patients will become RAI-refractory (RAIR), and it can be fatal if recurrent lesions are progressive. [6] [7] [8] [9] [10] [11] [12] RAIR is the major cause of thyroid cancerrelated death, which is also a challenge in the current management of the thyroid nodules.
In order to avoid needless RAI therapy, recognizing the RAIR cases in time is important for the patients to obtain more time for the effective therapy. Ultrasound (US) is useful for discriminating between benign and malignant lesions and is used as guidance for fine-needle aspiration biopsy (FNAB). [13] [14] [15] Previous studies demonstrated the good diagnostic efficacy of US for cervical lymph node metastasis. [16] Moreover, US is the preferred screening modality for postoperative follow-up and can help identify cervical lesions that are likely to be malignant. [17] [18] [19] [20] [21] [22] However, to our knowledge, the ultrasound characteristics of these cervical lesions of RAIR patients have not been reported. We reviewed the clinical, US and prognostic characteristics of patients with locally advanced or metastatic RAIR-DTC. In order to help distinguish metastasized cervical lymph nodes of RAIR-DTC patients from non RAIR-DTC patients.
Patients and methods
Institutional review board approval of our center ethics review committee was obtained for this study ethics review committee was obtained for this study, and the informed consents were obtained from all patients before enrollment. This study was conducted in accordance with the Declaration of Helsinki. This study is registered with Clinical Trails. gov (No. NCT02731352).
Patients and study design
Patients aged 18 years or older with histologically confirmed locally advanced or metastatic RAIR-DTC were prospectively recruited in this study. The inclusion criteria included at least 1 progressive lesion according to the RECIST (version 1.1); and meet the following definition of RAIR-DTC.
Patients were classified as RAIR-DTC if they met 1 of the following criteria:
1. had at least 1 measurable lesion without iodine uptake on 131I scan, 2. had 1 measurable lesion that had progressed within the past 12 months even it could take up radioiodine, or 3. received cumulative activity of 131I over 600 mCi.
Seventeen patients with histologically confirmed locally advanced or metastatic RAIR-DTC were enrolled Follow-up evaluations included measurement of thyroglobulin (Tg), anti-Tg antibody, and thyroid stimulating hormone (TSH) levels and periodic neck ultrasonography. Whole-body scans, computed tomography (CT), magnetic resonance imaging (MRI), or F-fluorodeoxyglucose positron emission tomography (PET) were performed for all patients with suspicion of recurrence.
Among the 17 patients, 15 patients had cervical lymph node metastasis, and 2 other patients had RAIR-DTC with visible pulmonal lesions on CT. The 15 patients with cervical lymph node metastasis were defined as the RAIR DTC group in the study. The US characteristics of the RAIR-DTC Group before RAI treatment were obtained. The clinical and US characteristics of the RAIR-DTC Group before RAI treatment were compared with cases of non RAIR-DTC cervical lymph node metastasis (Control Group). Patients who met the following criteria were included in the control group:
1. thyroidectomy performed during the first surgery due to pathologically confirmed DTC; and 2. recurrent or persistent metastatic cervical lymph nodes (LNs) derived from DTC were histologically confirmed during postoperative RAI therapy.
A gender-and age-matched control group comprising 59 patients was randomly selected.
Thyroid US examination and evaluation
All US examinations were performed with Phillips IU 22 (Philips Healthcare, Eindhoven, Netherlands), GE Logiq 9 (GE Healthcare, Milwaukee, WI, USA) devices equipped with 5 to 12 MHz linear-array transducer (TIS = 0.1, MI = 0.06). The patients were positioned in a supine position with dorsal flexion of the head.
The dynamic range, gain, depth, and focal zone were adjusted to optimize image quality during the examination. The maximum size of lesions was examined by US at the same site on each patient. The size, location, cystic appearance, hyperechogenic punctuations, hyperechogenic hilum, and vascularity were evaluated by US. US images were evaluated by 2 radiologists who were experienced in thyroid US and were blinded to the patients' clinical data and pathological results. In cases of a discrepancy between the 2 readers, a consensus was reached after a discussion.
Statistical analysis
Quantitative data are presented as the mean ± standard deviation (SD). Qualitative data are presented as frequencies.
The Shapiro-Wilk test was used to determine the presence of a normal distribution. For parametric data, an unpaired t test was used to evaluate differences between the 2 groups. For nonparametric data, differences between groups were analyzed using a Mann-Whitney U test. The Chi-Squared test with Yates correction and Fisher exact test were used to compare categorical variables. The study analyzed distant metastasis rates using the Kaplan-Meier method and log-rank testing. A value of P < .05 was considered statistically significant. Statistical analyses were performed with SPSS software (Version 19.0, SPSS Chicago, IL, USA).
Results

Clinical characteristics of RAI patients of different pathological types
Of the 17 patients included in our study, the postoperative pathological results revealed that 15 patients had PTC (papillary thyroid cancer), and 2 patients had poorly differentiated carcinoma (PDC). The characteristics of the 17 patients according to their pathological types are shown in Table 1 . The patients included 11 (64.7%) females and 6 (35.2%) males with a median age of 52.4 years. The median interval between Table 1 Clinical characteristics of 17 patients according to pathological type. diagnosis of RAIR and onset of illness (in terms of time frame from first diagnosis) was 9.6 years (range, 2 years∼33 years). The median interval between initial surgery and onset of illness was 29.9 months (range, 1 months∼264 months). Cervical lymph node metastasis was found in 15 patients (88.3%). The initial surgical procedures included lobectomy (5 patients, 23.5%), near-total thyroidectomy (5 patients, 29.4%), total thyroidectomy (7 patients, 41.1%) ( Table 2 ).
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Patients
US characteristics and differences between RAIR Group and Control Group
Among the 17 patients, cervical lymph node metastasis was found in 15 patients (88.3%). Of these lesions, 6 (40.0%) cases were found at central neck levels, 3 (20.0%) cases were found at lateral neck levels, and 6 (40.0%) cases were found at both central and lateral neck levels (Fig. 1) . We compared the US features of metastasized cervical LNs of RAIR patients with 59 lesions of metastasized cervical LNs from non RAI-DTC patients (Control Group). The sizes of the lymph nodes in the RAIR Group and Control Group were 2.0 ± 0.9 cm and 1.3 ± 0.7 cm, respectively (P = .03). The incidence of hyperechogenic punctuations was significantly higher (P = .004) in the Control Group than that in the RAIR Group. More lesions with visible flow were found in the RAIR Group (P = .04). More multiple lesions were found in the RAIR Group than that in the Control Group. Regarding the T staging of the thyroid nodules, more nodules with T1 were in the Control Group than that in the RAIR Group. The median serum Tg levels of the RAIR Group and Control Group were 459.2 IU/ml (3.9-2628.0 IU/ml) and 6.1 IU/ml (range 1.1-15.3 IU/ml), respectively (P = .03). Hyperechogenic hilum was absent in the majority of patients in both groups, but no statistical significance was detected between the 2 groups regarding hyperechogenic hilum ( Table 2 ).
Clinical courses for RAIR-DTC patients
All 17 patients included in our study were followed-up. The median follow-up period after onset of illness was 179 months. At the time of initial thyroid surgery, none of the patients showed distant metastasis. 17 (100.0%) patients developed distant metastasis (17 in the lung, 5 in bone tissue and 1 in the brain) during follow-up. The prognosis of DTC patients with RAIR-DTC were significantly worse than those of patients in Control Group (P = .001) (Fig. 2 ).
Discussion
An earlier identification of RAIR is highly necessary, which help timely prevent the patients from ineffective RAI therapy. In previous study, Smoking, tumor type (follicular thyroid cancer), extrathyroid extension, lymph node metastasis, and pN stage were highly correlated with the prevalence of RAIR DTC. [23] It may help obtain more time for the effective therapeutic options, such as tyrosine kinase inhibitor. Ultrasound (US) shows a high accuracy in cervical lymph node recurrence and diagnosing soft tissue lesions such as musculoskeletal disorders. [24] [25] [26] In 1 study with 76 postoperative PTC patients, the results showed that US showed higher diagnostic accuracy, sensitivity and specificity in diagnosing cervical lymph node recurrence with PTC, compared with those of PET (71.1%, 71.7%, and 69.6% vs 55.3%, 56.6%, and 52.2%). PET added diagnostic information in a limited number of patients with negative results on neck US. [27] Thus, we explored the difference in sonographic features between metastasized cervical LNs of RAIR-DTC patients and of non RAIR-DTC patients. Cervical lymph node metastasis was found in 88.3% of RAIR-DTC patients. Our result showed that LN size was a predictor, and the size of LN in RAIR-DTC patients (mean size, 2.0 cm) was larger than that in non RAIR-DTC patients (mean size, 1.30 cm), and more multiple lesions and more nodules with visible flow were found in the RAIR-DTC Group. Less hyperechogenic punctuations were found in RAIR-DTC group. While, regarding the T staging of the nodules more patients with T1 staging were in the Control Group than that in the RAIR Group. Distant metastasis rates for RAIR-DTC patients showed that the prognosis of these patients was significantly worse than those of patients with metastatic LNs alone in the Control Group (P < .01). Additionally, Moreover, none of the 17 patients died of RAIR-DTC during follow-up.
There are several limitations of our study. The main limitations of this study were the relatively small number of patients and the short follow-up period. Future studies with larger sample sizes and long-term follow-up are necessary to verify these results. Second, it may have been affected by selection bias as only patients who underwent both ultrasound and surgery were enrolled in the study.
In conclusion, RAIR patients had poorer prognosis than those with non-RAIR metastasis LNs alone. Cervical LN metastasis was found in most of RAIR-DTC patients. Ultrasound may help distinguish metastasized cervical LNs of RAIR patients. To minimize risk of RAIR, a long-term postoperative US evaluation should be completed.
